reports
- Daniel Ragonese
Aging Population, Advancements in Technology, and Rising Cancer Surviv...
Given shares in no-moat-rated Healius have been depressed over recent months, Jangho's proposal to acquire the healthcare company for AUD 3.25 per share is convenient timing. The bid falls short of our fair value estimate of AUD 3.50, and could be a shrewd bit of business for the Chinese company if they manage to pull it off. While the bid of AUD 3.25 represents a 46% premium to the stock price on Dec. 31, 2018, the last trading day before the proposal was announced, it is still more than 7% sho...
- Daniel Ragonese
Jangho Looks to Acquire Healius, But Indicative Offer Below our FVE
Given shares in no-moat-rated Healius have been depressed over recent months, Jangho's proposal to acquire the healthcare company for AUD 3.25 per share is convenient timing. The bid falls short of our fair value estimate of AUD 3.50, and could be a shrewd bit of business for the Chinese company if they manage to pull it off. While the bid of AUD 3.25 represents a 46% premium to the stock price on Dec. 31, 2018, the last trading day before the proposal was announced, it is still more than 7% sho...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.